Extracellular vesicles are tiny packages that cells release to communicate, loaded with proteins and genetic material. EVerZom's premise is that those shed by stem cells carry much of the healing effect of stem-cell therapy without the cells themselves. The obstacle has been making enough of them, consistently, to clinical standards. EVerZom, founded in Paris in 2019, set out to solve that.
The European Innovation Council granted €1.7 million to validate and scale EVerZom's production process. By the end of the project in April 2024 it had reached clinical-grade production. Since then the company has pivoted from making vesicles for others to developing its own therapy, raised €10 million with the EIC Fund among the investors, and plans its first human trial for 2026.
Company file
- Legal entity
- EVerZom SAS, SIREN 854 006 681
- Founded
- September 2019, Paris; headquarters moved to Strasbourg in April 2025
- Leadership
- Jeanne Volatron (co-founder, CEO); Nicolas Rousseau (managing director)
- Lead candidate
- EVerGel: stem-cell exosomes in a hydrogel, for Crohn's perianal fistulas
- Investors
- Capital Grand Est, EIC Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels
- EIC project
- ACROBAT, 1 May 2022 to 30 Apr 2024, closed
- Other public funding
- France 2030 grant of €3M (June 2025)
- Staff
- 10 to 19 (2023 register band)
What EVerZom Does Today
EVerZom is becoming a drug developer. Its October 2025 €10 million round, with Capital Grand Est, the EIC Fund, Sorbonne Venture by Audacia, Aloe Private Equity, Paris Business Angels, the Capital Cell platform and family offices, is meant to launch the first clinical trial of EVerGel in 2026. EVerGel combines exosomes from mesenchymal stem cells with a hydrogel that keeps them in place, to treat complex perianal fistulas in Crohn's disease, a painful complication that is hard to heal. The round also funds new indications in hepatology and dermatology and further industrialisation.
The production side continues. A €3 million France 2030 grant awarded in June 2025 supports scaling to 50-litre bioreactors, and the company moved its headquarters to Strasbourg in April 2025, according to Pappers.
"Our priority is to achieve a first clinical proof-of-concept in Crohn's perianal fistula."
Jeanne Volatron, co-founder and chief executive, EVerZom, October 2025The Technology: Turbulence as a Manufacturing Tool
Cells release more vesicles when they are mechanically stressed. EVerZom's patented process uses controlled turbulence in a bioreactor to trigger that release at scale. The project report says the team optimised the "Kolmogorov length", a measure of the smallest eddies in a turbulent flow, to produce "10 times more EVs in 1/10th of the time compared to current production methods". It extended the method to several cell types, including stem cells from fat tissue, umbilical cord and the endometrium.
What the EIC Project Promised, and What CORDIS Shows
ACROBAT, short for "toward democratisation of EV-based therapies", ran from 1 May 2022 to 30 April 2024. Its aim was to validate the production platform and scale it towards commercial batches. The report records clinical-grade production from human adipose stem cells "successfully in April 2024", scale-up to 10-litre bioreactors in clinical-compliant systems with yields consistent enough for Phase I/II trials, and a first long-term production partnership signed in 2023.
- GMP-grade vesicle productionDeliveredClinical-grade production achieved in April 2024, the project's final month.
- Scale-up towards commercial batchesDelivered10-litre clinical-compliant bioreactors; 50 litres now funded by France 2030.
- Production for third partiesPartialOne long-term partnership signed in 2023; the company's focus has since shifted to its own therapy.
What EVerZom Has Achieved Since
The shift in strategy is worth noting. ACROBAT was about democratising vesicle-based therapies by making production cheap and standard for the whole field. The company's public message now centres on its own pipeline. That is a common and often sensible move for biotech platforms, because a drug can be worth far more than a production service, but it means the EU-funded platform increasingly serves one company's drugs rather than the wider field.
The Money
EVerZom's accounts, reported by Pappers, show a lean company: net losses of €46,100 in 2021 and €288,000 in 2022, then a net profit of €417,000 in 2023; the public summary does not show what drove it. The 2024 accounts were filed with a confidentiality declaration. The register shows no insolvency proceedings and a €199,000 R&D aid payment in December 2024.
A rare EIC Fund follow-through
ACROBAT was a "grant first" award, with any equity decided later. The EIC Fund's participation in the October 2025 round shows that step being taken, which many 2021 winners cannot show.
Why Europe Should Care
The EU has funded vesicle research before, including the Horizon 2020 evFOUNDRY project. The ACROBAT objective itself names manufacturing as the issue that hampers the translation of vesicles to the clinic, and a European company that can produce clinical-grade vesicles at scale is a strategic asset for the whole field, whether it serves others or its own pipeline.
What the project promised
A validated, scalable production platform to democratise vesicle-based therapies.
What the record shows
GMP production and 10-litre scale delivered on time, EIC Fund equity secured, and a pivot towards the company's own Crohn's therapy, with no human data yet.
The Verdict
A manufacturing problem, solved
ACROBAT is one of the cleaner EIC outcomes: a concrete manufacturing goal, met within the project, followed by private and EIC equity. The next test is harder. EVerGel's animal results are striking, but animal results do not always carry over to people, and the first trial will show whether EVerZom's vesicles heal human fistulas. The EU paid for the factory; the clinic will decide its value.
EVerZom has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.
